Real-World Data on BRAF V600E-Mutated Metastatic Colorectal Cancer Treatment
Author Information
Author(s): Ros Javier, Ucha Jose Maria, Garcia-Galea Eduardo, Gomez Pablo, Martini Giulia, Balconi Francesca, Comas Raquel, Alonso Vicente, Rodriguez Marta, Baraibar Iosune, Salva Francesc, Saoudi Nadia, Alcaraz Adriana, Garcia Ariadna, Tabernero Josep, Elez Elena, Roncucci Luca
Primary Institution: Vall d’Hebron University Hospital
Hypothesis
What is the efficacy and safety of trifluridine/tipiracil in patients with BRAF V600E-mutated metastatic colorectal cancer?
Conclusion
Trifluridine/tipiracil provides modest survival benefits for patients with BRAF-mutant metastatic colorectal cancer, especially for those with good performance status.
Supporting Evidence
- Median overall survival for patients was 6.6 months.
- Patients with ECOG performance status 0 had a median survival of 12 months.
- Adverse events were similar to those reported in the overall colorectal cancer population.
Takeaway
This study looked at how well a cancer treatment works for patients with a specific gene mutation. It found that some patients can live longer with this treatment, especially if they are feeling well.
Methodology
A retrospective, multicenter, international cohort study analyzing patients with BRAF-mutated metastatic colorectal cancer treated with trifluridine/tipiracil.
Potential Biases
Potential biases due to the observational nature of real-world data collection.
Limitations
The study's retrospective nature and small sample size limit the generalizability of the findings.
Participant Demographics
Median age was 61 years, with 50% female and 77% having an ECOG performance status of 1.
Statistical Information
P-Value
0.3
Confidence Interval
95% CI 0.65–4.10
Statistical Significance
p=0.3
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website